Panel of leading biopharma executives will discuss how Earned Value Management can improve control over clinical development costs, payments, and accruals and facilitate compliance with Sarbanes-Oxley at the DIA 45th Annual Meeting in San Diego.
Chicago, IL (PRWEB) June 11, 2009 -- ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that Kristin Lucas, Senior Director, Clinical Services, will chair a cross-functional panel of clinical finance and operations experts in discussing "Improving Accrual and Contract Management with Earned Value Management" at the DIA 45th Annual Meeting. Held at the San Diego Convention Center, June 21-25, 2009, the meeting will bring together the biggest names from industry, regulatory, and academia to discuss the issues affecting global drug discovery and development.
Given the unprecedented challenges facing biopharma companies, the ability to accurately measure the performance of clinical studies and better manage cost and schedule components is becoming even more critical. Earned Value Management (EVM), a widely accepted practice in many industries, has gained significant momentum in clinical development based on its ability to:
*Accurately calculate accruals based on when work is actually performed
*Quickly determine if studies are on budget by task, provider or resources
*Effectively track project performance and timelines to determine project health
*Facilitate compliance with Sarbanes-Oxley
Lucas brings more than 15 years of experience in the pharmaceutical and biotech industry to the meeting, with extensive experience in clinical trial budgeting and contract management. Before joining ClearTrial, she led the Financ
Copyright©2009 Vocus, Inc.
All rights reserved